icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and GT 1 Patients With Prior Sofosbuvir Experience
 
 
  Reported by Jules Levin
EASL 2013 April 9-13 London, UK
 
Edward J. Gane,1 Robert H. Hyland,2 Di An,2 Phillip S. Pang,2 William T. Symonds,2 John G. McHutchison,2 Catherine A. Stedman3
1Auckland Clinical Studies Ltd, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, CA, USA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif